This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx
by Zacks Equity Research
CVS, BrightSpring, and GeneDx are tapping into AI, staffing trends, and precision medicine to drive future healthcare gains.
Should Invesco S&P 500 Pure Value ETF (RPV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RPV
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
by Zacks Equity Research
Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.
3 Medical Services Stocks Capitalizing on the Healthcare AI Boom
by Urmimala Biswas
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
by Sumit Singh
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis
by Zacks Equity Research
FLEX, CVS, URBN and EXEL stand out as GARP picks with strong growth outlooks and discounted PEG ratios.
4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio
by Urmimala Biswas
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
CVS Health's MBR Improves: Can It Sustain Amid Elevated Cost Trends?
by Moumi Mondal
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
by Zacks Equity Research
ZIMV launches RealGUIDE Software Suite and Implant Concierge in Japan to boost digital dental workflows.
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
by Zacks Equity Research
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Is it Wise to Retain Federal Realty Stock in Your Portfolio for Now?
by Zacks Equity Research
FRT leans on premium assets, strong tenants and mixed-use growth, but debt and digital retail trends cloud the outlook.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS Health Advances Digital Strategy: Is It the Next Revenue Pillar?
by Moumi Mondal
CVS unveils a $20B digital strategy to tackle healthcare gaps and reshape consumer health experiences.
Top Stock Reports for Netflix, Toyota Motor & Morgan Stanley
by Mark Vickery
NFLX gains momentum with 55% of new sign-ups on its ad tier and aims to double revenue by 2030 through global content.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
by Zacks Equity Research
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
by Sumit Singh
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.